Why A Structured System Matters 
How The System Helps You Succeed 
How Implementation Works 
What’s Included in the System 
Real Practice Outcomes 
Scaling a Profitable Practice 
Patient Demand 
Patient Education 
Staff Education 
Marketing 
Regenerative Medicine Platform
Franchise & PE Support 
Wharton’s Jelly
Exosomes
Anti-Aging
Aesthetic Treatments
Neurological
Autoimmune
Wound Care
Orthopedic Conditions
Clinical Trials
Articles
Research Institutes
BPC-157 / TB-500
BPC-157 and TB-500 are research peptides that are often studied together for their potential regenerative and healing properties. BPC-157 (Body Protection Compound-157) is a synthetic peptide derived from a protein in gastric juice, while TB-500 (Thymosin Beta-4 fragment) is a synthetic version of a naturally occurring peptide fragment involved in tissue repair and cell migration. Both are considered experimental compounds and are not FDA-approved for medical use.
How It Is Used In Research Settings
- BPC-157: Stimulates angiogenesis (new blood vessel formation), increases collagen production, reduces inflammation, and protects the gastrointestinal tract.
It has also been studied for potential neuroprotective effects. - TB-500: Promotes cell migration, supports wound healing, reduces fibrosis, and plays a role in actin regulation (a protein important for cell structure and movement).
- Synergy: When studied together, BPC-157 and TB-500 appear to have complementary effects on tissue repair, recovery, and systemic healing.
Proposed Uses (Research Areas)
- Muscle, tendon, and ligament healing: Both peptides have shown promise in accelerating recovery and strengthening connective tissues.
- Joint protection: Studied for reducing joint inflammation and improving mobility after injury.
- Gut health (BPC-157): Research indicates protective effects on the stomach lining and intestines in animal models.
- Cardiac and vascular repair (TB-500): Early studies suggest potential for improving heart and vascular tissue healing.
- Wound healing: Both peptides contribute to angiogenesis and collagen remodeling in soft tissue injuries.
Typical Research Dosages
Human clinical dosing has not been standardized. Protocols reported in research and anecdotal contexts include:
- BPC-157 injectable: 200–500 mcg daily, subcutaneous or intramuscular near the site of injury, typically for 2–4 weeks. Some use up to 1,000 mcg daily in more severe cases.
- BPC-157 oral: 250–500 mcg daily, though oral bioavailability is not well established.
- TB-500 injectable: 2–5 mg administered twice weekly for 4–6 weeks, followed by maintenance dosing monthly.
- Combination protocols: Some research settings use both peptides together, with BPC-157 for localized repair and TB-500 for systemic effects.
Important Considerations
- Regulatory status: Neither BPC-157 nor TB-500 is FDA-approved. Both are considered experimental research compounds.
- Evidence base: Most studies are preclinical (animal or cell culture). Human clinical trials are lacking, and results in humans remain uncertain.
- Safety: Generally well tolerated in short-term research studies, but long-term human safety has not been established.
Disclaimer
This information is provided for educational purposes only and is a summary of published research on BPC-157 and TB-500.
It is not intended as medical advice. These peptides are experimental, not FDA-approved, and should not be viewed as therapies for medical use.
This peptide is for research use only.